Kilpest has huge growth potential. Buy for 43% upside potential

Discussion in 'Latest Brokerage Stock Buy-Sell Reports' started by Vidhi Khanna, Sep 16, 2023.

  1. Vidhi Khanna

    Vidhi Khanna Active Member Staff Member

    Mar 19, 2015
    Likes Received:
    Kilpest's molecular diagnostics business is a niche segment with strong potential. Market size is Rs 300+cr with huge growth potential. It has 10%+ market share. Co is cash-rich (Rs 151 cr) & will earn FCF of Rs 69 cr over the next three years. It is at a discount of ~51% to average P/E ratio of peers. Buy for 43% upside

    Download research report